Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Middle East and Africa Biosimilars Deals

MS Pharma Partners With Mabxience For Bevacizumab In MENA Region

Follows Agreement With Alvion For Rosuvastatin/Ezetimibe In MENA

  • News

Executive Summary

Jordan-based MS Pharma has struck a deal with Insud Pharma subsidiary Mabxience to commercialize its bevacizumab biosimilar in the Middle East and North Africa region. The move comes after Mabxience partnered with Zentiva to commercialize bevacizumab in 21 European countries. Meanwhile, MS Pharma has also partnered with Alvion Pharma for rosuvastatin/ezetimibe in the MENA region.

Table

View full table

Related Content

Generics Bulletin
Generics Bulletin

Topics

Related Companies

Tags:
Middle East and Africa Biosimilars Deals
Latest Headlines

MS Pharma Bags Formycon’s Eylea Biosimilar Rights In MENA

Former Sandoz Exec Kellum Avoids Jail Time Over US Price Fixing

Deals In Bag, Dr Reddy’s Sharpens Top 5 Targeted Home Run

Majority Of US Patent Thickets Filed Post-FDA Approval, Study Finds

See All
UsernamePublicRestriction

Register

GB151203

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By